CRISPR-Based Gene Therapy Earns Beta Thalassemia Approval CRISPR-Based Gene Therapy Earns Beta Thalassemia Approval

Exa-cel earned its second FDA approval. The one-time therapy, which has a list price of $2.2 million in the United States, should be available for patients early this year.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news